Corneal dystrophies: Molecular genetics to therapeutic intervention-fifth ARVO/Pfizer ophthalmics research institute conference

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5391-5402

  Weiss, Jayne S ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MITOMYCIN C; RIBOFLAVIN;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CONGENITAL CORNEA DYSTROPHY; CORNEA DYSTROPHY; CORNEA TRANSPLANTATION; CYSTINOSIN GENE; CYSTINOSIS; DESCEMET STRIPPING ENDOTHELIAL KERATOPLASTY; FABRY DISEASE; GENE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GRANULAR LATTICE DYSTROPHY TYPE 2; HUMAN; KERATOCONUS; KERATOMILEUSIS; MOLECULAR GENETICS; NONHUMAN; PENETRATING KERATOPLASTY; PREVALENCE; PRIORITY JOURNAL; SCHNYDER CORNEAL DYSTROPHY; TGFBI GENE; ULTRAVIOLET A RADIATION;

CORNEAL DYSTROPHIES, HEREDITARY; HUMANS; MOLECULAR BIOLOGY;

EID: 79956039811     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4746     Document Type: Article

References (115)

1. Eye Bank Association of America. Statistical Report on Eye Banking Activity for 2008. Washington, DC: EBAA; 2009. Available (for purchase by nonmembers) at http://www.restoresight.org/donation/statistics.htm.
2. Williams KA Lowe MT, Bartlett CM, Kelly L, Coster DJ, eds. The Australian Corneal Graft Registry: 2007 Report. Adelaide, Australia: Flinders University Press; 2007:194.
3. Poinard C, Tuppin P, Loty B, Delbosc B. The French national waiting list for keratoplasty created in 1999: patient registration, indications, characteristics, and turnover (in French). J Fr Ophtalmol. 2003;26:911-919.
4. Jonasson F, Oshima E, Thonar EJ, Smith CF, Johannsson JH, Klintworth GK. Macular corneal dystrophy in Iceland: a clinical, genealogic, and immunohistochemical study of 28 patients. Ophthalmology. 1996;103:1111-1117.
5. Gwilliam R, Liskova P, Filipec M, et al. Posterior polymorphous corneal dystrophy in Czech families maps to chromosome 20 and excludes the VSX1 gene. Invest Ophthalmol Vis Sci. 2005;46: 4480-4484.
6. Rolland JS. Anticipatory loss: a family systems developmental framework. Fam Process. 1990;29:229-244.
7. Boss P. Insights: ambiguous loss-living with frozen grief. Harv Ment Health Lett. 1999;16:4-6.
8. Doka KJ. Grief: the constant companion of illness. Anesthesiol Clin. 2006;24:205-212.
9. Sobel S, Cowan CB. Ambiguous loss and disenfranchised grief: the impact of DNA predictive testing on the family as a system. Fam Process. 2003;42:47-57.
10. Weiss JS, Møller HU, Lisch W, et al. The IC3D classification of the corneal dystrophies. Cornea. 2008;27(suppl 2):S1-S83.
11. Chiou AG, Beuerman RW, Kaufman SC, Kaufman HE. Confocal microscopy in lattice corneal dystrophy. Graefes Arch Clin Exp Ophthalmol. 1999;237:697-701.
12. Chiou AG, Kaufman SC, Beuerman RW, Maitchouk D, Kaufman HE. Confocal microscopy in posterior polymorphous corneal dystrophy. Ophthalmologica. 1999;213:211-213.
13. Chiou AG, Kaufman SC, Kaufman HE, Beuerman RW. Clinical corneal confocal microscopy. Surv Ophthalmol. 2006;51:482-500.
14. Dhaliwal JS, Kaufman SC, Chiou AG. Current applications of clinical confocal microscopy. Curr Opin Ophthalmol. 2007;18: 300-307.
15. Brooks BP, Macdonald IM, Tumminia SJ, et al. Genomics in the era of molecular ophthalmology: reflections on the National Ophthalmic Disease Genotyping Network (eyeGENE). Arch Ophthalmol. 2008;126:424-425.
16. http://www.nei.nih.gov/resources/eyegene/professionals.asp. Accessed September 2009.
17. Blain D, Brooks BP. Molecular diagnosis and genetic counseling in ophthalmology. Arch Ophthalmol. 2007;125:196-203.
18. Jun RM, Tchah H, Kim TI, et al. Avellino corneal dystrophy after LASIK. Ophthalmology. 2004;111:463-468.
19. Groenouw Knötchenförmige Hornhauttrübungen (Noduli corneae). Arch Augenheilkunde. 1890;21:281-289.
20. Fuchs E. Ueber knoetchenfoermige Hornhauttruebung. Albrecht von Graefes Arch Ophthalmol. 1902;53:423-438.
21. Jones ST, Zimmerman LE. Macular dystrophy of the cornea (Groenouw type II): clinicopathologic report of two cases with comments concerning its differential diagnosis from lattice dystrophy (Biber-Haab-Dimmer). Am J Ophthalmol. 1959;47:1-16.
22. Klintworth GK, Vogel FS. Macular corneal dystrophy: an inherited acid mucopolysaccharide storage disease of the corneal fibroblast. Am J Pathol. 1964;45:565-586.
23. Klintworth GK, Hawkins HK, Smith CF. Acridine orange particles in cultured fibroblasts: a comparative study of macular corneal dystrophy, systemic mucopolysaccharidoses types I-H and II, and normal controls. Arch Pathol Lab Med. 1979;103:297-299.
24. Klintworth GK, Smith CF. Macular corneal dystrophy: studies of sulfated glycosaminoglycans in corneal explant and confluent stromal cell cultures. Am J Pathol. 1977;89:167-182.
25. Akama TO, Nishida K, Nakayama J, et al. Macular corneal dystrophy type I and type II are caused by distinct mutations in a new sulphotransferase gene. Nat Genet. 2000;26:237-241.
26. Klintworth GK, Smith CF, Bowling BL. CHST6 mutations in North American subjects with macular corneal dystrophy: a comprehensive molecular genetic review. Mol Vis. 2006;12:159-176.
27. Sultana A, Klintworth GK, Thonar EJ, Vemuganti GK, Kannabiran C. Immunophenotypes of macular corneal dystrophy in India and correlation with mutations in CHST6. Mol Vis. 2009;15:319-325.
28. Munier FL, Korvatska E, Djemai A, et al. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997; 15:247-251.
29. Pericak-Vance MA. Analysis of genetic linkage data for Mendelian traits. Curr Protoc Hum Genet. 2001;Chapter 1:Unit 1.4.
30. Pericak-Vance MA. Overview of linkage analysis in complex traits. Curr Protoc Hum Genet. 2001;Chapter 1:Unit 1.9.
31. Patil N, Nouri N, McAllister L, Matsukaki H, Ryder T. Singlenucleotide polymorphism genotyping using microarrays. Curr Protoc Hum Genet. 2001;Chapter 2:Unit 2.9.
32. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet. 2009;10:551-564.
33. Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet. 2009;374:340-350.
34. Joshi VA, Mancini-DiNardo D, Funke BH. Selection of a platform for mutation detection. Curr Protoc Hum Genet. 2008;Chapter 7:Unit 7.15.
35. Stone EM. Finding and interpreting genetic variations that are important to ophthalmologists. Trans Am Ophthalmol Soc. 2003; 101:437-484.
36. Mandal MN, Heckenlively JR, Burch T, et al. Sequencing arrays for screening multiple genes associated with early-onset human retinal degenerations on a high-throughput platform. Invest Ophthalmol Vis Sci. 2005;46:3355-3362.
37. Yzer S, Leroy BP, De Baere E, et al. Microarray-based mutation detection and phenotypic characterization of patients with Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2006;47:1167-1176.
38. ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn. 2008;10:484-492.
39. Runager K, Garcia-Castellanos R, Valnickova Z, et al. Purification, crystallization and preliminary X-ray diffraction of wild-type and mutant recombinant human transforming growth factor betainduced protein (TGFBIp). Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009;65:299-303.
40. Runager K, Enghild JJ, Klintworth GK. Focus on molecules: Transforming growth factor beta induced protein (TGFBIp). Exp Eye Res. 2008;87:298-299.
41. Biswas S, Munier FL, Yardley J, et al. Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum Mol Genet. 2001;10:2415-2423.
42. Aldave AJ, Rayner SA, Salem AK, et al. No pathogenic mutations identified in the COL8A1 and COL8A2 genes in familial Fuchs corneal dystrophy. Invest Ophthalmol Vis Sci. 2006;47:3787-3790.
43. Vithana EN, Morgan PE, Ramprasad V, et al. SLC4A11 mutations in Fuchs endothelial corneal dystrophy. Hum Mol Genet. 2008; 17:656-666.
44. Mehta JS, Vithana EN, Tan DT, et al. Analysis of the posterior polymorphous corneal dystrophy 3 gene, TCF8, in late-onset Fuchs endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2008;49:184-188.
45. Kniestedt C, Taralczak M, Thiel MA, Stuermer J, Baumer A, Gloor BP. A novel PITX2 mutation and a polymorphism in a 5-generation family with Axenfeld-Rieger anomaly and coexisting Fuchs' endothelial dystrophy. Ophthalmology. 2006;113:1791-1798.
46. Afshari NA, Li YJ, Pericak-Vance MA, Gregory S, Klintworth GK. Genome-wide linkage scan in Fuchs endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2009;50:1093-1097.
47. Iyengar SK, Abboud HE, Goddard KA, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56:1577-1585.
48. Iyengar SK. The quest for genes causing complex traits in ocular medicine: successes, interpretations, and challenges. Arch Ophthalmol. 2007;125:11-18.
49. Gottsch JD, Sundin OH, Liu SH, et al. Inheritance of a novel COL8A2 mutation defines a distinct early-onset subtype of fuchs corneal dystrophy. Invest Ophthalmol Vis Sci. 2005;46:1934-1939.
50. Sundin OH, Jun AS, Broman KW, et al. Linkage of late-onset Fuchs corneal dystrophy to a novel locus at 13pTel-13q12.13. Invest Ophthalmol Vis Sci. 2006;47:140-145.
51. Sundin OH, Broman KW, Chang HH, Vito EC, Stark WJ, Gottsch JD. A common locus for late-onset Fuchs corneal dystrophy maps to 18q21.2-q21.32. Invest Ophthalmol Vis Sci. 2006;47:3919-3926.
52. Riazuddin SA, Eghrari AO, Al-Saif A, et al. Linkage of a mild late-onset phenotype of Fuchs corneal dystrophy to a novel locus at 5q33.1-q35.2. Invest Ophthalmol Vis Sci. 2009;50:5667-5771.
53. Rabinowitz YS. The genetics of keratoconus (review). Ophthalmol Clin North Am. 2003;16:607-620, vii.
54. Wang Y, Rabinowitz YS, Rotter JI, Yang H. Genetic epidemiological study of keratoconus: evidence for major gene determination. Am J Med Genet. 2000;93:403-409.
55. Li X, Yang H, Rabinowitz YS. Keratoconus: classification scheme based on videokeratography and clinical signs. J Cataract Refract Surg. 2009;35:1597-1603.
56. Rabinowitz YS, Dong L, Wistow G. Gene expression profile studies of human keratoconus cornea for NEIBank: a novel cornea- expressed gene and the absence of transcripts for aquaporin 5. Invest Ophthalmol Vis Sci. 2005;46:1239-1246.
57. McMonnies CW. Abnormal rubbing and keratectasia. Eye Contact Lens. 2007;33:265-271.
58. Lema I, Sobrino T, Duran JA, Brea D, Diez-Feijoo E. Subclinical keratoconus and inflammatory molecules from tears. Br J Ophthalmol. 2009;93:820-824.
59. Saghizadeh M, Chwa M, Aoki A, et al. Altered expression of growth factors and cytokines in keratoconus, bullous keratopathy and diabetic human corneas. Exp Eye Res. 2001;73:179-189.
60. Lema I, Duran JA. Inflammatory molecules in the tears of patients with keratoconus. Ophthalmology. 2005;112:654-659.
61. Shoham A, Hadziahmetovic M, Dunaief JL, Mydlarski MB, Schipper HM. Oxidative stress in diseases of the human cornea. Free Radic Biol Med. 2008;45:1047-1055.
62. Cristina Kenney M, Brown DJ. The cascade hypothesis of keratoconus. Cont Lens Anterior Eye. 2003;26:139-146.
63. Ebihara N, Funaki T, Matsuda H, Okumura K, Murakami A, Ra C. Corneal abnormalities in the NC/Nga mouse: an atopic dermatitis model. Cornea. 2008;27:923-929.
64. Hayashida Y, Akama TO, Beecher N, et al. Matrix morphogenesis in cornea is mediated by the modification of keratan sulfate by GlcNAc 6-O-sulfotransferase. Proc Natl Acad Sci USA. 2006;103: 13333-13338.
65. Kao WW, Liu CY, Converse RL, et al. Keratin 12-deficient mice have fragile corneal epithelia. Invest Ophthalmol Vis Sci. 1996; 37:2572-2584.
66. Liu CY, Birk DE, Hassell JR, Kane B, Kao WW. Keratocan-deficient mice display alterations in corneal structure. J Biol Chem. 2003; 278:21672-21677.
67. Liu Y, Peng X, Tan J, Darling DS, Kaplan HJ, Dean DC. Zeb1 mutant mice as a model of posterior corneal dystrophy. Invest Ophthalmol Vis Sci. 2008;49:1843-1849.
68. Saika S, Shiraishi A, Liu CY, et al. Role of lumican in the corneal epithelium during wound healing. J Biol Chem. 2000;275:2607-2612.
69. Kao WW. Ocular surface tissue morphogenesis in normal and disease states revealed by genetically modified mice. Cornea. 2006;25:S7-S19.
70. Saika S, Ikeda K, Yamanaka O, et al. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol. 2005;166:1405-1418.
71. Chikama T, Liu CY, Meij JT, et al. Excess FGF-7 in corneal epithelium causes corneal intraepithelial neoplasia in young mice and epithelium hyperplasia in adult mice. Am J Pathol. 2008;172: 638-649.
72. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
73. Lee JH, Stulting RD, Lee DH, Lee CS, Kim WC, Kim EK. Exacerbation of granular corneal dystrophy type II (Avellino corneal dystrophy) after LASEK. J Refract Surg. 2008;24:39-45.
74. Kim TI, Pak JH, Chae JB, Kim EK, Tchah H. Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy. Cornea. 2006;25:220-223.
75. Ha BJ, Kim TI, Choi SI, et al. Mitomycin C does not inhibit exacerbation of granular corneal dystrophy type II induced by refractive surface ablation, Cornea. 2010;29;490-496.
76. Cetin E, Yaman A, Berk AT. Etiology of childhood blindness in Izmir, Turkey. Eur J Ophthalmol. 2004;14:531-537.
77. Blohme J, Tornqvist K. Visual impairment in Swedish children. I. Register and prevalence data. Acta Ophthalmol Scand. 1997;75: 194-198.
78. Bois E, Feingold J, Frenay P, Briard ML. Infantile cystinosis in France: genetics, incidence, geographic distribution. J Med Genet. 1976;13:434-438.
79. Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007;147:242-250.
80. Stokes MB, Jernigan S, D'Agati VD. Infantile nephropathic cystinosis. Kidney Int. 2008;73:782-786.
81. Kalatzis V, Serratrice N, Hippert C, et al. The ocular anomalies in a cystinosis animal model mimic disease pathogenesis. Pediatr Res. 2007;62:156-162.
82. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007;52:97-105.
83. Kleta R, Gahl WA. Pharmacological treatment of nephropathic cystinosis with cysteamine. Expert Opin Pharmacother. 2004;5: 2255-2262.
84. Kleta R, Bernardini I, Ueda M, et al. Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr. 2004; 145:555-560.
85. Schneider JA. Treatment of cystinosis: simple in principle, difficult in practice. J Pediatr. 2004;145:436-438.
86. Khan AO, Latimer B. Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis. Am J Ophthalmol. 2004;138:674-675.
87. Kinoshita S, Nishida K, Dota A, et al. Epithelial barrier function and ultrastructure of gelatinous drop-like corneal dystrophy. Cornea. 2000;19:551-555.
88. Takaoka M, Nakamura T, Ban Y, Kinoshita S. Phenotypic investigation of cell junction-related proteins in gelatinous drop-like corneal dystrophy. Invest Ophthalmol Vis Sci. 2007;48:1095-1101.
89. Tsujikawa M, Kurahashi H, Tanaka T, et al. Homozygosity mapping of a gene responsible for gelatinous drop-like corneal dystrophy to chromosome 1p. Am J Hum Genet. 1998;63:1073-1077.
90. Ha NT, Chau HM, Cung le X, et al. A novel mutation of M1S1 gene found in a Vietnamese patient with gelatinous droplike corneal dystrophy. Am J Ophthalmol. 2003;135:390-393.
91. Ren Z, Lin PY, Klintworth GK, et al. Allelic and locus heterogeneity in autosomal recessive gelatinous drop-like corneal dystrophy. Hum Genet. 2002;110:568-577.
92. Tsujikawa M, Kurahashi H, Tanaka T, et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat Genet. 1999;21:420-423.
93. Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:2035-2040.
94. Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg. 2009;35:621-624.
95. Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590-594.
96. Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation line. Cornea. 2006;25:1057-1059.
97. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: longterm results. J Cataract Refract Surg. 2008;34:796-801.
98. Weiss JS. Schnyder corneal dystrophy. Curr Opin Ophthalmol. 2009;20:292-298.
99. Weiss JS. Schnyder's dystrophy of the cornea: a Swede-Finn connection. Cornea. 1992;11:93-101.
100. Weiss JS. Schnyder crystalline dystrophy sine crystals: recommendation for a revision of nomenclature. Ophthalmology. 1996;103: 465-473.
101. Weiss JS. Visual morbidity in thirty-four families with Schnyder crystalline corneal dystrophy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:616-648.
102. Crispin SM. Crystalline corneal dystrophy in the dog: histochemical and ultrastructural study. Cornea. 1988;7:149-161.
103. Crispin S. Lipid Keratopathy in the Dog. Edinburgh, Scotland, UK: University of Edinburgh; 1984.
104. Crispin SM. Lipid deposition at the limbus. Eye. 1989;3:240-250.
105. Crispin S. Ocular lipid deposition and hyperlipoproteinaemia. Prog Retin Eye Res. 2002;21:169-224.
106. Crispin SM, Bolton CH, Downs LG. Plasma lipid and lipoprotein profile of working and pet border collies. Vet Rec. 1992;130:185-186.
107. Downs LG, Crispin SM, LeGrande-Defretin V, et al. The effect of dietary changes on plasma lipids and lipoproteins of six Labrador retrievers. Res Vet Sci. 1997;63:175-181.
108. Gaynor PM, Zhang WY, Weiss JS, Skarlatos SI, Rodrigues MM, Kruth HS. Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in Schnyder's corneal dystrophy. Arterioscler Thromb Vasc Biol. 1996;16:992-999.
109. Weiss JS, Rodrigues MM, Kruth HS, Rajagopalan S, Rader DJ, Kachadoorian H. Panstromal Schnyder's corneal dystrophy: ultrastructural and histochemical studies. Ophthalmology. 1992;99: 1072-1081.
110. McGarvey TW, Nguyen TB, Malkowicz SB. An interaction between apolipoprotein E and TERE1 with a possible association with bladder tumor formation. J Cell Biochem. 2005;95:419-428.
111. Orr A, Dube MP, Marcadier J, et al. Mutations in the UBIAD1 gene, encoding a potential prenyltransferase, are causal for Schnyder crystalline corneal dystrophy. PLoS One. 2007;2:e685.
112. Weiss JS, Kruth HS, Kuivaniemi H, et al. Mutations in the UBIAD1 gene on chromosome short arm 1, region 36, cause Schnyder crystalline corneal dystrophy. Invest Ophthalmol Vis Sci. 2007; 48:5007-5012.
113. Nickerson ML, Kostiha BN, Brandt W, et al. UBIAD1 mutation alters a mitochondrial prenyltransferase to cause Schnyder corneal dystropy. PLoS ONE 2010;5:e10760.
114. Weiss JS. Molecular genetics and the classification of the corneal dystrophies: what is next? Am J Ophthalmol. 2009;148:477-478.
115. Weiss JS, Kruth HS, Kuivaniemi H, et al. Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function. Am J Med Genet A. 2008;146:271-283.